TCGX closes oversubscribed $600 million Asia life sciences fund
TCGX said the new fund will focus on biotechnology companies based in Asia and will operate separately from its flagship funds. The firm also said it is expanding operations to Asia with new offices in Shanghai and Hong Kong.